Lightnews — Scholar-powered news

Suzanne E. Schindler @suzanneeschindler.bsky.social · 2d

Congrats!

Reposted by Suzanne E. Schindler

Ian Kremer @leadcoalition.bsky.social · 17d

New landscape of the diagnosis of Alzheimer's disease www.thelancet.com/journals/lan... by @thelancet.com

#Alzheimers #dementia #biomarkers #neuroscience #NeuroSkyence

New landscape of the diagnosis of Alzheimer's disease

Alzheimer's disease involves a drastic departure from the cognitive, functional, and behavioural trajectory of normal ageing, and is both a dreaded and highly prevalent cause of disability to individu...

www.thelancet.com

3 14 30

Suzanne E. Schindler @suzanneeschindler.bsky.social · 18d

Review of Alzheimer's diagnostics from The Lancet:

New landscape of the diagnosis of Alzheimer's disease
www.sciencedirect.com/science/arti...

#ENDALZ

1

Reposted by Suzanne E. Schindler

Alzheimer's Association @alzassociation.bsky.social · 21d

We're proud to share that over the last year, we invested $112.2 million in our research programs—the largest single-year on record—bringing our total active & committed investments to over $450 million. Help us continue the momentum: alz.org/donate. #ENDALZ #BrainHealth

5 18

Reposted by Suzanne E. Schindler

Jason Hassenstab @ctrlab.org · 27d

New paper from the lab. First author @mwelhaf.bsky.social, now in a TT position at North Carolina A&T. We wanted to know how environmental contexts and self-reported distractions impacted cognitive #EMA in older adults. mhealth.jmir.org/2025/1/e71578 1/n

Impacts of Environmental Distractions and Interruptions on Unsupervised Digital Cognitive Assessments in Older Adults: Cognitive Ecological Momentary Assessment Study

Background: Unsupervised cognitive assessments are becoming commonly used in studies of aging and neurodegenerative diseases. Because assessments are completed in everyday environments and without a p...

mhealth.jmir.org

1 4 10

Suzanne E. Schindler @suzanneeschindler.bsky.social · Jul 14

"Clocks" that relate amyloid and tau PET to time were used to examine the timing of biomarker changes (including plasma biomarkers) in Alzheimer disease. Plasma Aβ42/40 changes very early! onlinelibrary.wiley.com/doi/10.1002/...

#ENDALZ

Timing of Changes in Alzheimer's Disease Plasma Biomarkers as Assessed by Amyloid and Tau PET Clocks

Objective The objective of this study was to evaluate the timing of change of Alzheimer's disease (AD) plasma biomarkers (Aβ42/Aβ40, p-tau217, p-tau181, GFAP, and NfL) from six different assay platf.....

onlinelibrary.wiley.com

2 2

Suzanne E. Schindler @suzanneeschindler.bsky.social · Jul 14

Practical information for clinicians on selection and interpretation of different biomarker tests for Alzheimer disease:

practicalneurology.com/diseases-dia...

Selection and Interpretation of Biomarker Tests for Alzheimer Disease

Diagnostic tests for Alzheimer disease can help guide clinical management, but results must be interpreted carefully.

practicalneurology.com

1 1

Suzanne E. Schindler @suzanneeschindler.bsky.social · Jun 4

Alzheimer's disease drug development pipeline: 2025 - Cummings - 2025 - Alzheimer's & Dementia: Translational Research & Clinical Interventions - Wiley Online Library alz-journals.onlinelibrary.wiley.com/doi/10.1002/...

Alzheimer's disease drug development pipeline: 2025

Clinical trials for Alzheimer's disease (AD) must be registered on clinicaltrials.gov. The registry presents a variety of types of information related to the planned clinical trial. We assess clinic...

alz-journals.onlinelibrary.wiley.com

1 1

Reposted by Suzanne E. Schindler

WashU Medicine @washumedicine.bsky.social · May 15

From clinical trials to practice, WashU Medicine’s Memory Diagnostic Center offers top-tier, end-to-end Alzheimer's care. Now, a promising new study paves the way for clinics worldwide to adopt our elevated standard of outpatient care and infrastructure. 🔗 medicine.washu.edu/news/drug-to...

1 1

Suzanne E. Schindler @suzanneeschindler.bsky.social · May 25

Development of Simple Risk Scores for Prediction of Brain β-Amyloid and Tau Status in Older Adults With Mild Cognitive Impairment: A Machine Learning Approach url:https://academic.oup.com/psychsocgerontology/article-abstract/doi/10.1093/geronb/gbaf085/8125623

1

Reposted by Suzanne E. Schindler

Ian Kremer @leadcoalition.bsky.social · May 24

An Expensive Alzheimer’s Lifestyle Plan Offers False Hope, Experts Say

www.nytimes.com

3 4

Reposted by Suzanne E. Schindler

Yakeel T. Quiroz, PhD @ytquiroz.bsky.social · May 21

Genetic studies reveal protective variants that delay Alzheimer's, offering insights into new therapies.

Be sure to check out our new review on protective genetic variants in Lancet Neurology, along with the editorial that features this research!

www.sciencedirect.com/science/arti...

Protective genetic variants against Alzheimer's disease

Genetic studies can offer powerful insights for the development of disease-modifying therapies for Alzheimer's disease. Protective genetic variants th…

www.sciencedirect.com

7 34

Reposted by Suzanne E. Schindler

NPR @npr.org · May 18

UPDATE: More than 5,000 homes were impacted, and 38 people were injured after an EF3 tornado tore across St. Louis. via @stlpublicradio.bsky.social

‘I just fell to my knees and cried’: St. Louisans face devastating damage after tornado that killed 5

More than 5,000 homes were impacted, and 38 people were injured after an EF3 tornado tore across St. Louis.

www.stlpr.org

400 1.7K 5.7K

Reposted by Suzanne E. Schindler

Alzheimer's Association @alzassociation.bsky.social · May 15

❌ FALSE: “For 20 years…we were directing Alzheimer’s research to one hypothesis. And any other hypotheses were shut down.” - Sec. Kennedy

Over the last decade, less than 14% of new National Institutes of Health (NIH) Alzheimer’s projects focused on amyloid beta as the therapeutic target. 🧵(1/4)

1 36 67

Reposted by Suzanne E. Schindler

Dave Weisman @dweisman.bsky.social · May 14

The Wash U lecanemab paper is a hard act to follow. But here’s a combo experience with a private clinic and U Wash.

link.springer.com/article/10.1...

Monoclonal antibody administration in an academic institution and private neurological practice: a tale of two clinics - Journal of Neurology

The emergence of monoclonal antibody (MABs) drugs since the FDA approval of lecanemab has resulted in dramatic changes in the clinical approach and management of early-stage Alzheimer’s disease (AD). ...

link.springer.com

1 3

Suzanne E. Schindler @suzanneeschindler.bsky.social · May 12

We have been trying to learn everything we can from our experiences with amyloid-targeting treatments to improve patient care. We present the findings from our first 234 patients treated with lecanemab in JAMA Neurology: ja.ma/42TLKzx

#ENDALZ
@WashUNeurology

3

Suzanne E. Schindler @suzanneeschindler.bsky.social · May 8

Check out a great podcast featuring Joe Therriault
explaining how to diagnose Alzheimer's disease by integrating the clinical impression with plasma biomarkers: pca.st/episode/b729...

He makes PPV/NPV so easy to understand!

From his recent paper:
rdcu.be/eldzt

Web Player - Pocket Casts

Listen to your favorite podcasts online, in your browser. Discover the world's most powerful podcast player.

pca.st

Suzanne E. Schindler @suzanneeschindler.bsky.social · May 3

Looks awesome, have a great time!

1

Reposted by Suzanne E. Schindler

Dr. Donna Wilcock @wilcocklab.bsky.social · Apr 28

Thank you @60minutes.bsky.social for giving the NIH freezes, termination, and proposed budget cuts the attention they deserve. ALL Americans, regardless of party, will feel this impact to their health far beyond one administration. www.cbsnews.com/video/nih-cu...

Federal cuts to National Institutes of Health could threaten medical progress

Former National Institutes of Health Director Dr. Francis Collins, who abruptly left his NIH research lab in February, fears aggressive downsizing could impact Americans’ health.

www.cbsnews.com

9 14

Reposted by Suzanne E. Schindler

Dave Weisman @dweisman.bsky.social · Apr 27

WIth 94 sequential patients on lecanemab, what did we learn?

www.vumedi.com/video/real-w...

Real-World Experience With Long-Term Lecanemab Treatment: A Retrospective Chart Review in Early Alzheimer's Disease

A video from David Weisman, posted on Apr 17, 2025.

www.vumedi.com

1 2 3

Suzanne E. Schindler @suzanneeschindler.bsky.social · Apr 17

We need confidence that AD treatments will benefit our patients and at this point clinical endpoints are needed. In the future we can work to validate biomarkers as surrogate outcomes. Here is a link to more discussion about these issues on Alzforum:
www.alzforum.org/news/researc...

Is It Time to Approve Drugs Based on Amyloid Removal? | ALZFORUM

www.alzforum.org

1 3

Reposted by Suzanne E. Schindler

Vincent Planche @vincentplanche.bsky.social · Apr 4

Happy to share the work of Vincent Bouteloup, which has just been published in JAMA Neurology and presented this morning at the AD/PD Conference! jamanetwork.com/journals/jam...

Cognitive Phenotyping and Interpretation of Alzheimer Blood Biomarkers

This cohort study investigates if the clinical phenotype of patients without dementia is associated with blood phosphorylated tau 217 interpretation.

jamanetwork.com

1 6 15

Reposted by Suzanne E. Schindler

Dave Weisman @dweisman.bsky.social · Apr 2

Big loss today. Alzheon overall trial was negative. But there were provocative findings. www.neurologylive.com/view/valiltr...

Valiltramiprosate Demonstrates Greater Promise in Milder Forms of Alzheimer Disease, Phase 3 APOLLOE4 Study Shows

Although valiltramiprosate failed to distinguish itself from placebo on the primary end point, the drug performed significantly better among mild MCI participants vs those with mild Alzheimer disease.

www.neurologylive.com

1 1 3

Suzanne E. Schindler @suzanneeschindler.bsky.social · Apr 2

time.com/7273006/alzh...

An Alzheimer’s Blood Test Might Predict Advanced Disease

The test, which is not yet commercially available, focuses on a different form of the protein tau.

time.com

2 2

Reposted by Suzanne E. Schindler

Alzheimer's Association @alzassociation.bsky.social · Apr 1

Cuts made today by the Department of Health and Human Services (HHS) may undermine our nation’s response to the dementia public health crisis. Read our statement: bit.ly/43BtxHU.

Alzheimer’s Association Sounding the Alarm Over the Threat of Elimination of Alzheimer’s Programs at HHS, CDC

Alzheimer's Association statement: Actions taken by the Department of Health & Human Services may undermine the response to the dementia public health crisis.

bit.ly

17 20